(MENAFN- Straits Research)
Market Overview
The North America Autoinjectors Market size was valued at USD 5.86 billion in 2025 and is projected to grow from USD 6.37 billion in 2026 to reach USD 12.33 billion by 2034, growing at a CAGR of 8.62% during the forecast period 2026–2034.
Highlights
Anaphylaxis dominates the market by therapy.
Disposable dominates the market by type.
Home care dominates the market by end-user.
Autoinjectors are pre-filled syringes with a tip held in place by a spring. When a sliding motion is used to inject the device into the body, it turns on and gives a measured dose of a medicine. Autoinjectors are used to give yourself epinephrine to avoid anaphylaxis or to quickly relieve pain from a migraine, as well as for other medical and emergency treatments. Autoinjectors have several benefits, such as making people less afraid of needles, lowering the chance of getting a needle stuck, keeping the dose quality consistent, and helping people be more successful.
Download a Free Sample To learn more about this report,
Market Dynamics
North America Autoinjectors Market Drivers
Increasing Incidences of Anaphylactic Shock
Anaphylactic shock demands immediate medical attention. EpiPens, which give epinephrine in an anaphylactic emergency, are autoinjectors. According to CDC data, food allergies, a primary cause of anaphylactic shock, are rising in the U.S. Food allergies in children under 18 increased by 50% between 1997 and 2011. Common allergens include peanuts, tree nuts, shellfish, milk, eggs, and soy. Thus, this factor can act as a major driver in the market.
North America Autoinjectors Market Restraints
Increasing Preference for Alternative Drug Delivery Modes
Oral medication, inhalation devices, and transdermal patches have advanced in the North American pharmaceutical sector. These alternatives increase patient compliance, convenience, and autoinjector demand. Patients may choose oral or non-invasive delivery techniques over injections. Due to their widespread use, oral drugs are convenient and familiar. This slows market growth.
North America Autoinjectors Market Opportunities
Streamline Regulatory Guidelines
In North America, simplifying rules has opened up possibilities for growth in the autoinjectors market. Regulatory bodies like the FDA have made the approval process easier, reducing the time and money needed for product creation and entry. This has led to faster entry to the market, lower costs, more innovation, and easier access for patients to more advanced autoinjector devices. Streamlining rules has helped the industry grow by increasing players, encouraging innovation, and ensuring people get better treatments quickly.
North America Autoinjectors Market Segmentation Analysis
By Product Type
The North America Autoinjectors Market is segmented into Disposable Autoinjectors and Reusable Autoinjectors. Disposable autoinjectors are designed for single-use administration and provide convenience, simplified handling, and reduced requirements for cleaning or maintenance, making them suitable for patients requiring regular self-administration of medications. Reusable autoinjectors can be used multiple times with replaceable medication cartridges or doses and are designed to provide longer-term usability and potentially reduce device waste. Disposable autoinjectors account for a significant share of demand because of their ease of use, portability, and suitability for self-administration in homecare settings, while reusable devices are gaining attention because of their durability and potential cost benefits over repeated treatment cycles.
Increasing prevalence of chronic diseases, growing adoption of self-administered therapies, rising healthcare expenditure, and increasing patient preference for convenient drug delivery are supporting demand across both product categories. Disposable devices benefit from their simple operation and reduced maintenance requirements, while reusable autoinjectors are supported by advancements in device design, dose flexibility, and sustainability considerations. Increasing adoption of biologic therapies, growing emphasis on patient-centric treatment, and technological improvements such as connected and electronically assisted injection systems are expected to create further opportunities for autoinjector manufacturers across North America.
Request Customization to receive a tailored report.
By Indication
The North America Autoinjectors Market is segmented into Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, and Other Therapies. Rheumatoid arthritis and multiple sclerosis are important applications because patients with these chronic conditions may require repeated administration of injectable medications over extended treatment periods. Diabetes represents a major application area due to the large patient population requiring regular medication administration, while autoinjectors for anaphylaxis provide rapid and convenient emergency delivery of epinephrine. Other therapies include additional chronic and acute conditions for which self-administered or caregiver-assisted injectable treatments can improve convenience and treatment adherence.
Increasing prevalence of chronic diseases, growing demand for biologic and injectable therapies, rising awareness of emergency treatment for anaphylaxis, and increasing preference for self-administration are supporting market growth across these indications. The adoption of autoinjectors is particularly supported by their ability to simplify injection procedures and improve patient confidence outside healthcare facilities. Growing availability of specialty pharmaceuticals, development of user-friendly drug-device combinations, and increasing focus on improving medication adherence are expected to expand the use of autoinjectors across rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapeutic areas.
By End Use
The North America Autoinjectors Market is segmented into Homecare Settings, Hospitals & Clinics, and Ambulatory Surgical Centers. Homecare settings represent an important end-use segment because autoinjectors allow patients or caregivers to administer prescribed medications without requiring frequent visits to healthcare facilities. Hospitals and clinics use autoinjectors for patient treatment, training, supervised administration, and emergency applications, particularly for therapies requiring professional medical oversight. Ambulatory surgical centers may use autoinjectors for selected injectable therapies and postoperative or supportive treatment where appropriate. The convenience and portability of these devices make them particularly relevant to home-based medication administration.
Growing preference for home healthcare, increasing adoption of self-injection therapies, efforts to reduce healthcare costs, and the need to improve patient convenience are supporting demand across end-use settings. Homecare adoption is benefiting from the expansion of specialty medications and chronic disease management outside hospitals, while hospitals and clinics remain important for diagnosis, treatment initiation, patient education, and supervised administration. Ambulatory surgical centers are also contributing to demand as outpatient procedures expand and healthcare providers increasingly seek efficient medication-delivery options. Continued development of user-friendly, compact, and technologically advanced autoinjectors is expected to strengthen adoption across North America.
Speak to an Analyst to discuss market opportunities.
Regional Analysis
The North American autoinjectors market is analyzed by country in the U.S., Canada, and Mexico. The U.S. dominated the market and is expected to grow at a CAGR of 15.2% during the forecast period.
In 2022, North America made the most revenue in the autoinjectors market. This is because many people have diseases and have better access to improved treatments for anaphylaxis. Since rheumatoid arthritis, anaphylaxis, diabetes, migraines, heart disease, and food allergies are becoming more common, there is a high demand for autoinjectors.
U.s
During the time frame of the forecast, the United States autoinjectors market is projected to have a large share of the North American market. The market is growing because of the rise in chronic and specific diseases, the number of regulatory approvals, and technological advances in the healthcare industry. According to Food Allergy Research and Education, about 33.1 million Americans have food allergies. This includes 5.99 million children under 18 years old, one in thirteen. Since more people have anaphylaxis and other allergies in the United States, the FDA has to approve new products more quickly. Self-administered drugs are in higher demand because more people have chronic and inflammatory diseases.
On the other hand, according to the Centers for Disease Control and Prevention, 24% of adults in the U.S., or 58.5 million people, have arthritis. It is the top cause of work disability, costing $303.5 billion annually in medical care and lost wages. Also, the most common type of arthritis is osteoarthritis. When doctors say someone has arthritis, it is hard for them to do their daily tasks.
Canada
The Canadian autoinjectors market is also expected to have a high growth rate in terms of revenue. This is because Canada has a more advanced healthcare system, more people want quality goods, and the government is investing more money. Canada's market is growing because more people are getting chronic diseases, paying attention to their health, and using autoinjectors to give themselves drugs. Bausch Health, Canada, said in an October 2020 release that EmeradeTM epinephrine autoinjectors are now available in pharmacies all over Canada. Emerade is a new autoinjector for epinephrine that gives Canadians a second choice. More people will be able to get autoinjector goods, which will help the market grow in the country as a whole.
List of Key and Emerging Players in North America Autoinjectors Market
Pfizer Inc. (Meridian Medical Technologies, Inc.)
AbbVie Inc.
Sanofi
SHL Group
Becton, Dickinson, and Company
Biogen
Mylan N.V.
Novartis AG
Antares Pharma
Key Industry Developments
May 2026: embecta completed the acquisition of Owen Mumford Holdings Limited, expanding its drug delivery portfolio with the Aidaptus® next-generation autoinjector platform. The acquisition strengthens embecta's position in autoinjectors and supports the delivery of therapies for diabetes, obesity, autoimmune diseases, and anaphylaxis.
January 2026: BD expanded its partnership with Ypsomed to develop a 5.5 mL BD NeopakTM XtraFlowTM glass prefillable syringe compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform, advancing large-volume self-injection solutions for biologic therapies.
May 2025: Ypsomed and CamDiab expanded the availability of the mylife CamAPS FX app on iOS, strengthening the mylife Loop automated insulin delivery ecosystem and enhancing digital diabetes management for patients using connected injection systems.
April 2025: SHL Medical expanded its autoinjector manufacturing capacity in North America by advancing production and automation investments to support increasing demand for biologic drug delivery devices and large-scale commercial autoinjector programs.
Report Scope
Comments
No comment